Tonix Pharmaceuticals Q2 2024 GAAP EPS $(19.28) Misses $(3.27) Estimate, Sales $2.208M Miss $3.500M Estimate
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals reported a Q2 2024 GAAP EPS of $(19.28), significantly missing the $(3.27) estimate. Sales were $2.208 million, also missing the $3.500 million estimate.
August 19, 2024 | 10:06 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Tonix Pharmaceuticals reported a significant earnings miss for Q2 2024, with GAAP EPS of $(19.28) versus the $(3.27) estimate and sales of $2.208 million missing the $3.500 million estimate.
The significant miss on both EPS and sales estimates is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100